Jazz Pharmaceuticals plc (JAZZ) Financial Statements (2024 and earlier)

Company Profile

Business Address FIFTH FLOOR, WATERLOO EXCHANGE
DUBLIN, 4
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments8815911,058637310386
Cash and cash equivalents8815911,058637310386
Receivables651563396356264224
Inventory, net of allowances, customer advances and progress billings7141,07395795343
Inventory7141,07395795343
Prepaid expense9213162392523
Other current assets267252152796877
Other undisclosed current assets  1,075440515215
Total current assets:2,6062,6112,8401,6301,234968
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization 56  
Operating lease, right-of-use asset7387129139
Property, plant and equipment   128132200170
Intangible assets, net (including goodwill)7,4878,9803,1533,3613,6593,927
Goodwill1,6931,828958920928948
Intangible assets, net (excluding goodwill)5,7947,1522,1952,4412,7312,979
Deferred income tax assets376311255221
Other noncurrent assets554126484316
Other undisclosed noncurrent assets233263576742
Total noncurrent assets:8,2299,6873,6963,9093,9694,155
TOTAL ASSETS:10,83512,2996,5365,5395,2035,124
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities894776405326307245
Taxes payable102511122
Accounts payable9110027484124
Accrued liabilities803666353268265199
Deferred revenue0235
Debt3131246333341
Deferred revenue and credits9
Contract with customer, liability5
Other undisclosed current liabilities7     
Total current liabilities:933809654364345294
Noncurrent Liabilities
Long-term debt and lease obligation5,6936,1061,9891,7251,5631,540
Long-term debt, excluding current maturities5,6936,0191,8491,5741,5631,540
Liabilities, other than long-term debt1,1231,418234338228193
Deferred revenue and credits16
Deferred revenue  025
Contract with customer, liability10
Deferred income tax liabilities9441,301130224
Other liabilities107117101109219177
Operating lease, liability7287140151
Other undisclosed noncurrent liabilities     309383
Total noncurrent liabilities:6,8167,5242,2222,0632,1012,117
Total liabilities:7,7508,3332,8762,4282,4462,411
Equity
Equity, attributable to parent, including:3,0863,9653,6603,1112,7572,713
Common stock000000
Additional paid in capital3,4773,5352,6342,2662,1141,935
Accumulated other comprehensive loss(1,126)(400)(134)(223)(198)(141)
Retained earnings7348301,1601,068841918
Other undisclosed equity, attributable to parent111111
Total equity:3,0863,9653,6603,1112,7572,713
TOTAL LIABILITIES AND EQUITY:10,83512,2996,5365,5395,2035,124

Income Statement (P&L) ($ in millions)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues3,6593,0942,3642,1621,8911,619
Revenue, net1,601
Cost of revenue(502)(440)(149)(238)  
Gross profit:3,1572,6542,2151,9241,8911,619
Operating expenses(3,223)(2,484)(1,837)(1,392)(1,276)(1,090)
Operating income (loss):(66)170378532615529
Nonoperating income (expense)
(loss, Foreign Currency Transaction, before Tax)
(19)(4)(3)(6)(7)(10)
Interest and debt expense (0)(0)(76)(59)(57)(38)
Other undisclosed loss from continuing operations before equity method investments, income taxes(288)(278)(24)(13)(22)(40)
Income (loss) from continuing operations before equity method investments, income taxes:(373)(113)275454529441
Loss from equity method investments(10)(1)(3)(4)(2)(1)
Income (loss) from continuing operations before income taxes:(383)(114)272450527440
Income tax expense (benefit)159(216)(34)73(80)48
Income (loss) from continuing operations:(224)(330)239523447488
Income (loss) before gain (loss) on sale of properties:(330)239523447488
Net income (loss) available to common stockholders, basic:(224)(330)239523447488
Interest on convertible debt      
Net income (loss) available to common stockholders, diluted:(224)(330)239523447488

Comprehensive Income ($ in millions)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net income (loss):(224)(330)239523447488
Other comprehensive income (loss) (266)89(26)(57)176
Comprehensive income (loss):(224)(596)328498390664
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(725)     
Comprehensive income (loss), net of tax, attributable to parent:(949)(596)328498390664

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: